Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674997 · ClinicalTrials.gov registry record
GAS-Hem Feasibility Study
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 44
- Enrollment target
NCT02674997: Completed study, sponsored by Baxalta now part of Shire.
NCT02674997 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02674997 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the feasibility and acceptability of the Standardized Goal Attainment Scaling menu for Hemophilia (GAS-Hem) as a patient reported outcome (PRO) measure to monitor clinical progress in participant-identified goal areas in individuals with hemophilia A.
Primary Outcome
The GAS-Hem is an online instrument for setting and tracking personalized goals related to hemophilia. The GAS-Hem uses a 5-point scale to record the degree of attainment in relation to individually defined goal areas between an established baseline (scaled as -1) and follow-up time points (here, 6 weeks and 12 weeks). The scale range is +2 (much better outcome) to -2 (much worse outcome), where 0 represents the desired outcome. The process includes a facilitator to ensure that the outcome descr
Interventions
- BIOLOGICAL Factor VIII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-08-05 |
| Est. Completion | 2016-11-02 |
What the finished NCT02674997 record still lists
NCT02674997 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Factor VIII is the first listed.
NCT02674997 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02674997 about?
NCT02674997 is a clinical study titled "GAS-Hem Feasibility Study". The purpose of this study is to investigate the feasibility and acceptability of the Standardized Goal Attainment Scaling menu for Hemophilia (GAS-Hem) as a patient reported outcome (PRO) measure to monitor clinical progress in participant-identified goal areas in individuals with hemophilia A.
What is the current status of trial NCT02674997?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2016-08-05. Estimated completion is 2016-11-02.
What interventions are being tested in trial NCT02674997?
The interventions under investigation include: Factor VIII (BIOLOGICAL).
Who is sponsoring clinical trial NCT02674997?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI